UroGen Pharma Revenue and Competitors
Estimated Revenue & Valuation
- UroGen Pharma's estimated annual revenue is currently $33.5M per year.
- UroGen Pharma received $162.1M in venture funding in January 2019.
- UroGen Pharma's estimated revenue per employee is $161,739
- UroGen Pharma's total funding is $422.1M.
Employee Data
- UroGen Pharma has 207 Employees.
- UroGen Pharma grew their employee count by 9% last year.
UroGen Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Quality | Reveal Email/Phone |
3 | Head Distribution Chain and Enterprise Systems | Reveal Email/Phone |
4 | VP, Market Access | Reveal Email/Phone |
5 | Head Biostatistics and Programming | Reveal Email/Phone |
6 | VP Manufacturing and Supply chain | Reveal Email/Phone |
7 | EVP Research and Development and Technical Operation | Reveal Email/Phone |
8 | VP, Pharmaceutical Research and Development | Reveal Email/Phone |
9 | Controller | Reveal Email/Phone |
10 | EVP, Talent, Advocacy and Communications | Reveal Email/Phone |
UroGen Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1232.4M | 3593 | 3% | N/A | N/A |
What Is UroGen Pharma?
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel (mitomycin urothelial gel) and VesiGel (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen Pharma is headquartered in Raanana, Israel with U.S. headquarters in New York.
keywords:N/A
$422.1M
Total Funding
207
Number of Employees
$33.5M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
UroGen Pharma News
UroGen Pharma (NASDAQ:URGN) Upgraded by Zacks Investment Research to Hold. Posted by admin on Apr 20th, 2022. Share on Twitter Share on Facebook Share on...
InvestorsObserver is giving Urogen Pharma Ltd (URGN) an Analyst Rating Rank of 59, meaning URGN is ranked higher by analysts than 59% of...
UroGen Pharma (NASDAQ:URGN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application to begin a...
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 18, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Company has entered into a strategic funding agr ...
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 18, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the fourth quarter and full year en ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $73.5M | 207 | 6% | N/A |
#2 | $31.2M | 207 | -4% | $14M |
#3 | $50.1M | 207 | -2% | N/A |
#4 | $33M | 207 | N/A | N/A |
#5 | $36.4M | 207 | N/A | N/A |
UroGen Pharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2019-01-29 | $162.1M | Undisclosed | J.P. Morgan | Article |